Catalyst Biosciences, Inc.
South San Francisco
California
United States
189 articles about Catalyst Biosciences, Inc.
-
It was another busy week for clinical trials. Here’s a look.
-
22NW: Catalyst Biosciences Needs Change Now
9/27/2019
22NW, LP is one of the largest shareholders of Catalyst Biosciences, Inc with ownership of approximately 6% of the Company's outstanding shares.
-
Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors
7/8/2019
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the Phase 2 trial of its subcutaneous (SQ) Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) for prophylaxis met the primary endpoint of significantly reducing the annualized bleed rate (ABR) in patients with hemophilia A or B with inhibitors.
-
Catalyst Biosciences Announces Oral and Poster Presentations at the International Society on Thrombosis and Haemostasis
7/1/2019
Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the upcoming International Society for Thrombosis and Hemostasis(ISTH) meeting being held in Melbourne, Australia from July 6-10, 2019.
-
Catalyst Biosciences to Present at the Jefferies 2019 Global Healthcare Conference
5/28/2019
Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Jefferies 2019 Global Healthcare Conference at 2:30 p.m. EDT on Tuesday, June 4, 2019 in New York.
-
Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update
5/2/2019
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2019 and provided a corporate update.
-
Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration
4/29/2019
Catalyst Biosciences, Inc.(NASDAQ: CBIO), and Mosaic Biosciences today announced the presentation of new data on pegylated CB 2782 (CB 2782-PEG), Catalyst’s preclinical anti-C3 candidate being developed for the treatment of geographic atrophy (GA) associated dry age-related macular degeneration (dry AMD) at the 2019 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held in Vancouver, British Columbia, from April 28 - May 2, 2019.
-
Catalyst Biosciences to Present at The Needham & Company 18th Annual Healthcare Conference
4/3/2019
Catalyst Biosciences, Inc., Inc. (NASDAQ:CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Needham & Company 18th Annual Healthcare Conference at 12:50 p.m. EDT on Tuesday, April 9, 2019 at the Westin Grand Central Hotel in New York.
-
Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B
4/2/2019
Catalyst Biosciences, Inc. (Nasdaq:CBIO), today announced the initiation of enrollment in a Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for the treatment of hemophilia B.
-
Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated)
4/1/2019
Catalyst Biosciences, Inc. (Nasdaq: CBIO) today announced that the European Commission has awarded orphan designation of its Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) for the treatment of haemophilia B (with or without inhibitors).
-
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2018 Operating & Financial Results and Provides a Corporate Update
3/7/2019
Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced its operating and financial results for the fourth quarter and full-year ending December 31, 2018 and provided a corporate update.
-
Catalyst Biosciences Announces Poster Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting
3/6/2019
Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the presentation of a poster, in collaboration with partner Mosaic Biosciences, at the 2019 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held in Vancouver, British Columbia, from April 28-May 2, 2019.
-
Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
2/8/2019
Catalyst Biosciences, Inc. (NASDAQ: CBIO), presented updated interim data from the Phase 2/3 trial of subcutaneous prophylactic Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) currently being developed for the treatment of hemophilia A or B with inhibitors. The data were delivered in an oral presentation at the 12TH Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being held Feb. 6-8, 2019 in Prague.
-
Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
2/6/2019
atalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications presented preclinical proof-of-concept data of CB 2679d-GT Factor IX gene therapy in hemophilia B mice.
-
Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference
2/5/2019
Catalyst Biosciences, Inc. (Nasdaq: CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Annual BIO CEO & Investor Conference, being held in New York City on February 11-12, 2019.
-
Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Hemophilia and Allied Disorders
1/31/2019
Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced oral and poster presentations at the 12TH Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being held in Prague from February 6-8, 2019.
-
Catalyst Biosciences Announces Proposed Public Offering of Common Stock - Feb. 13, 2018
2/13/2018
All of the shares in the offering are to be sold by the Company.
-
Catalyst Biosciences Announces Pricing of Public Offering of Common Stock - Feb. 13, 2018
2/13/2018
Additionally, the Company has granted the underwriters an option to purchase up to an additional 441,176 shares of its common stock, at the price to the public.
-
Catalyst Biosciences Announces Positive Top-Line Data from Phase I/II Study of Subcutaneous CB 2679d/ISU304 in Individuals With Hemophilia B
2/9/2018
Results from the trial showed a continuous linear increase in Factor IX activity levels following daily dosing of CB 2679d for six days.
-
Catalyst Biosciences Initiates Phase II/III Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B With Inhibitors
1/4/2018
This Phase 2 open-label, subcutaneous efficacy trial in individuals with hemophilia A or B with inhibitors will evaluate the ability of MarzAA to eliminate, or minimize, spontaneous bleeding episodes.